YUSIMRY® (adalimumab-fkjp)

About Meitheal Pharmaceuticals

Meitheal Pharmaceuticals is a private, commercial-stage biopharma company focused on generic injectables and biosimilars. Leveraging a partnership-driven model, it has built a diverse pipeline and product portfolio targeting therapeutic areas such as anti-infectives, oncology, diabetes, fertility, and immunology. The company emphasizes robust manufacturing, steady supply, and rapid market response to address unmet needs and improve drug affordability. Its recent expansion into biosimilars with the acquisition of YUSIMRY® and launch of products like liraglutide injection signals a strategic growth phase.

Therapeutic Areas

Other Immunology & Inflammation Drugs